Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
26 hedge funds and large institutions have $2.2M invested in Hepion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 1 closing their positions.
5,100% more call options, than puts
Call options by funds: $52K | Put options by funds: $1K
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
39% less capital invested
Capital invested by funds: $3.61M → $2.2M (-$1.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$48.6K |
| 2 |
Morgan Stanley
New York
|
+$26.6K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$8.03K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$7.61K |
| 5 |
Renaissance Technologies
New York
|
+$5.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$29.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.2K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$19.9K |
| 4 |
VF
Virtu Financial
New York
|
-$19.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $156 | – | – | – |
|
27
Barclays
London,
United Kingdom
| $93 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $54 | – | – | – |
|
|
S
29
SignatureFD
Atlanta,
Georgia
| $1 | – | – | – |
|
30
UBS Group
Zurich,
Switzerland
| – | -$5K | -11 | Closed |
|
HEPA Hedge Fund Activity: Q4 2022 in Review
26 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2022, worth a combined $2.2M — down 39% from $3.61M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HEPA positions and 1 closed out — a net gain of 1 holder — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $48.6K. The largest seller was Bank of New York Mellon, cutting an estimated $29.2K.
- 26 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2022, up from 25 in Q3 2022.
- Funds reported $2.2M of Hepion Pharmaceuticals stock for Q4 2022, down 39% quarter-over-quarter.
- 2 funds opened new Hepion Pharmaceuticals positions in Q4 2022 and 1 closed out, a net change of +1 holder.
- The largest Hepion Pharmaceuticals buyer in Q4 2022 was Envestnet Asset Management, an estimated $48.6K added.
- The largest Hepion Pharmaceuticals seller in Q4 2022 was Bank of New York Mellon, an estimated $29.2K sold.
Based on aggregated 13F filings for Q4 2022.